One of the greatest forces in wealth-building is the power of compounding. That is why every portfolio needs some set-it-and-forget-it stocks. When you find a good compounder, you should hold it forever.It is well known that investors do poorly timing the market. Due to the psychological nature of investing, most investors tend to buy at the top and sell at the bottom. As a result, they end up underperforming the market indices.Similarly, trying to time the tops and bottoms in the best-in-class compounders ...

While innovations such as artificial intelligence have become all the rage, there’s another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven’t considered the sector, it’s really time to focus on biotech stocks.First, let’s get the obvious matter out of the way: biotech stocks benefit broadly from a permanently relevant narrative. That doesn’t mean individual companies are guaranteed to rise. It’s just that the concept of addressing diseases an ...

AstraZeneca (AZN) announced positive results from the phase III NIAGARA study, which evaluated Imfinzi in patients with muscle-invasive bladder cancer (MIBC).Study participants who were enrolled in the NIAGARA study were randomized to receive Imfinzi plus chemotherapy or chemotherapy alone before cystectomy (bladder removal surgery), followed by Imfinzi or no further treatment after surgery.The study achieved statistically significant and clinically meaningful improvement in its primary endpoint of event-fr ...

There are multiple reasons to consider exposure to pharmaceutical stocks for the long-term portfolio. First, pharma stocks have a low-beta and provide and help in reducing the overall beta of a portfolio that’s overweight growth stocks. Further, pharma stock represents a business that’s relatively immune to economic shocks.At the same time, well established pharma companies have healthy cash flows and therefore sustained value creation through dividends. With these factors in consideration, investors should ...

You won't need much money to start investing in these great stocks.A low price doesn't necessarily mean low quality. That's true with lots of products and services. And it's true with stocks, too.We asked Three Motley Fool contributors to name no-brainer healthcare stocks to buy for under $100 right now. Here's why they picked AstraZeneca (AZN 0.41%), Bristol Myers Squibb (BMY 2.17%), and Pfizer (PFE).AstraZeneca is a growth beast with loads of potential upsideDavid Jagielski (AstraZeneca): Shares of AstraZ ...

AstraZeneca (AZN) announced that the European Commission (EC) has approved Truqap (capivasertib) in combination with Faslodex (fulvestrant) for a breast cancer indication.The EC has approved Truqap in combination with Faslodex for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors have qualifying alterations in the PIK3CA, AKT1 or PTEN genes following recurrence or progression on or after an endocrine-based regimen.Following ...

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The National Cancer Institute's (NCI) funding of research projects is predicted to empower the Pancreatic Cancer Market to grow. A report from Future Market Insights said that: "… the increasing adoption of therapeutic strategies is catapulting the pancreatic cancer market forward. Unlike traditional therapeutic methods such as chemotherapy, targeted therapy isolates receptor sites in cancer cells while causing no harm to t ...

AstraZeneca (AZN) announced that a phase III study evaluating its newly approved breast cancer drug, Truqap (capivasertib), for treating advanced or metastatic triple-negative breast cancer (TNBC), has failed to meet its dual primary endpoints.The CAPItello-290 study investigated the safety and efficacy of Truqap in combination with paclitaxel (chemotherapy) versus placebo in combination with paclitaxel for the first-line treatment of patients with locally advanced (inoperable) or metastatic TNBC.In the stu ...

Astrazeneca (AZN) closed at $79.31 in the latest trading session, marking a -0.35% move from the prior day. This move lagged the S&P 500's daily gain of 0.77%. At the same time, the Dow added 0.49%, and the tech-heavy Nasdaq gained 0.95%.The pharmaceutical's shares have seen an increase of 3.5% over the last month, surpassing the Medical sector's gain of 1.49% and falling behind the S&P 500's gain of 3.71%.Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upco ...

AstraZeneca (AZN) announced that the FDA has approved its blockbuster cancer drug Imfinzi (durvalumab) plus chemotherapy, followed by Imfinzi monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer.The approval for expanded use of Imfinzi was based on data from a prespecified exploratory subgroup analysis by MMR status in the phase III DUO-E study.Data from the study showed that treatment with Imfinzi in combination with carboplatin and ...